Short-Term Augmentation of Fluoxetine with Olanzapine in the Treatment of Poststroke Depression

Short-Term Augmentation of Fluoxetine with Olanzapine in the Treatment of Poststroke Depression: An Open-label ,Randomized Controlled Study

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-11001749

Enrollment

Unknown

Registered

2011-11-29

Start date

2009-01-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Poststroke Depression

Interventions

Experimental:fluoxetine and olanzapine

control:fluoxetine

Eligibility

Sex/Gender

All

Age

54 Years to 69 Years

Inclusion criteria

Inclusion criteria: 1. After CT or MRI confirmed,accord with the 4th national cerebrovascular disease meeting diagnosis standard; 2. Meet DSM-IV of depressive disorders diagnostic criteria; 3. HAMD24 score 24 scores; 4. Never use antidepressant drugs in past years before the enrollment.

Exclusion criteria

Exclusion criteria: 1. Serious liver and kidney disease; 2. Epilepsy history; 3. For any reason of the white blood cells or neutrophils reduced.

Design outcomes

Primary

Measure	Time frame
HAMD;	—

Countries

China

Contacts

Public ContactZhonglin Liu

zhonglinliu@126.com+86 13719438236

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026